Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017
Summary
Glucagon Like Peptide 2 Receptor (GLP2R) - Glucagon-like peptide 2 receptor (GLP-2R) is a protein encoded by the GLP2R gene. GLP2R, a G protein-coupled receptor superfamily member is expressed in the gut. GLP2 stimulates intestinal growth and up regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. GLP2 prevents intestinal hypoplasia resulting from total parenteral nutrition.
Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders and Toxicology which include indications Short Bowel Syndrome, Chemotherapy Effects, Diabetes, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes.
The latest report Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Glucagon Like Peptide 2 Receptor (GLP2R)
- The report reviews Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucagon Like Peptide 2 Receptor (GLP2R)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucagon Like Peptide 2 Receptor (GLP2R) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Glucagon Like Peptide 2 Receptor (GLP2R) - Overview 6
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment 12
Assessment by Mechanism of Action 12
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development 17
Hanmi Pharmaceuticals Co Ltd 17
Naia Ltd 17
Shire Plc 18
Tasly Pharmaceutical Group Co Ltd 18
Zealand Pharma AS 19
Glucagon Like Peptide 2 Receptor (GLP2R) - Drug Profiles 20
FE-203799 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
glepaglutide - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
GXG-8 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
HM-15910 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NB-1002 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
teduglutide - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ZPGG-23 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ZPGG-72 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
Glucagon Like Peptide 2 Receptor (GLP2R) - Dormant Products 34
Glucagon Like Peptide 2 Receptor (GLP2R) - Product Development Milestones 35
Featured News & Press Releases 35
Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome 35
Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome 36
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Pediatric Patients with Short Bowel Syndrome (SBS) 36
May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 37
Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 38
Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 38
Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 39
Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 39
Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 40
Jun 17, 2014: Zealand presented new data on GLP-1/GLP-2 novel peptide therapeutics from its preclinical diabetes pipeline at the American Diabetes Association’s (ADA) 74th Scientific Sessions 41
Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 42
Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 42
Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 43
Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 45
Jan 30, 2013: New Peer-reviewed Publication Offers Guidance For Integrating Gattex For Injection Into Management Of Short Bowel Syndrome 45
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Indication, H2 2017 9
Number of Products under Development by Companies, H2 2017 10
Products under Development by Companies, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 17
Pipeline by Naia Ltd, H2 2017 17
Pipeline by Shire Plc, H2 2017 18
Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 18
Pipeline by Zealand Pharma AS, H2 2017 19
Dormant Projects, H2 2017 34
List of Figures
Number of Products under Development by Stage of Development, H2 2017 7
Number of Products under Development by Therapy Areas, H2 2017 8
Number of Products under Development by Top 10 Indications, H2 2017 9
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 15
Number of Products by Stage and Molecule Types, H2 2017 15
